Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CX11 · 3 trials · 4 indications
AUC0-24 of of CX11 (VCT220)
Cmax of CX11 (VCT220)
Tmax of CX11 (VCT220)
| Arm | Type | Description |
|---|---|---|
| Placebo group | PLACEBO_COMPARATOR | - |
| 40 mg group | EXPERIMENTAL | - |
| 80 mg group | EXPERIMENTAL | - |
| 120 mg group | EXPERIMENTAL | - |
| 160 mg group | EXPERIMENTAL | - |
| 200 mg group | EXPERIMENTAL | - |
| 200 mg fast titration group | EXPERIMENTAL | - |
| 200 mg slow titration group | EXPERIMENTAL | - |
| Fasted-Fed Arm | EXPERIMENTAL | Fasted-Fed Group |
| Fed-Fasted Arm | EXPERIMENTAL | Fed-Fasted Group |
| Name | Type | Description |
|---|---|---|
| CX11 | DRUG | CX11 tablets administered orally once daily (QD) |
| Placebo | OTHER | Matching placebo tablets administered orally once daily (QD) |
| CX11 (VCT220) | DRUG | CX11 (VCT220) administered orally to participants who are in fasted/fed state in the first 6 consecutive days, and in fed/fasted state on the 7th day |
Inclusion Criteria Participants who meet all of the following criteria will be eligible to participate in this study: * Adults aged 18 to 75. * Diagnosis of type 2 diabetes for at least 6 months. * HbA1c between 7.0% and 10.5%. * Body mass index (BMI) between 23 and 50 kg/m². * Body weight stable ...
Top 20 of 33 competitors